Clinical Trial Update: Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) [Phase 2]

View source ↗

Summary

Phase 2 dose-range finding study of BF2.649 in obstructive sleep apnea completed, evaluating effects on excessive daytime sleepiness.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Obstructive Sleep Apnea

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: Bioprojet | Conditions: Obstructive Sleep Apnoea, Excessive Daytime Sleepiness | Phase 2 | Status: COMPLETED